Study of Autologous Platelet Rich Plasma Infusion to Restore Ovarian Function in Women with Premature Ovarian Insufficiency Aged 25 to 39

What this Trial Is About

Researchers are evaluating the potential of autologous platelet-rich plasma PRP intra-ovarian infusion to restore ovarian function and promote folliculogenesis in women with premature ovarian insufficiency POI. This randomized, triple-blind controlled trial focuses on women aged 25 to 39 who experience amenorrhea or irregular menstrual cycles along with elevated follicle-stimulating hormone FSH levels. PRP, which is enriched with growth factors such as VEGF, EGF, and PDGF, has been used in other medical fields but its effect on ovarian rejuvenation is not yet fully understood. The study compares two groups one receiving the autologous PRP intra-ovarian infusion and the other receiving a placebo infusion using platelet-free plasma PFP. Both treatments involve infusion directly into the ovaries. Participants must have a normal karyotype and discontinue any hormone or complementary therapies at least three months before enrolling. The trial is conducted in a parallel design with randomized allocation to treatment groups. Participants are monitored over a three-month follow-up period with monthly evaluations assessing menstrual cycle restoration, serum hormone levels including FSH, AMH, LH, estradiol, and progesterone, as well as antral follicle count. These assessments help researchers understand the effect of the treatments on ovarian function. The total study duration extends until July 2028, with ongoing safety and effectiveness monitoring throughout the treatment and follow-up phases.

Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients